

# Vitamin D<sub>3</sub> supplementation in patients with frequent respiratory tract infections: a randomised and double-blind intervention study

Peter Bergman,<sup>1,2,3</sup> Anna-Carin Norlin,<sup>2,4</sup> Susanne Hansen,<sup>2</sup> Rokeya Sultana Rekha,<sup>5</sup> Birgitta Agerberth,<sup>5</sup> Linda Björkhem-Bergman,<sup>6</sup> Lena Ekström,<sup>6</sup> Jonatan D Lindh,<sup>6</sup> Jan Andersson<sup>3</sup>

**To cite:** Bergman P, Norlin A-C, Hansen S, *et al*. Vitamin D<sub>3</sub> supplementation in patients with frequent respiratory tract infections: a randomised and double-blind intervention study. *BMJ Open* 2012;**2**: e001663. doi:10.1136/bmjopen-2012-001663

► Prepublication history and additional material for this paper are available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2012-001663>).

Received 13 June 2012  
Revised 15 November 2012  
Accepted 15 November 2012

This final article is available for use under the terms of the Creative Commons Attribution Non-Commercial 2.0 Licence; see <http://bmjopen.bmj.com>

PB and ACN contributed equally to this study.

For numbered affiliations see end of article.

**Correspondence to**  
Dr Peter Bergman;  
[peter.bergman@ki.se](mailto:peter.bergman@ki.se)

## ABSTRACT

**Background:** Low serum levels of 25-hydroxyvitamin D<sub>3</sub> are associated with an increased risk of respiratory tract infections (RTIs). Clinical trials with vitamin D<sub>3</sub> against various infections have been carried out but data are so far not conclusive. Thus, there is a need for additional randomised controlled trials of effects of vitamin D<sub>3</sub> on infections.

**Objective:** To investigate if supplementation with vitamin D<sub>3</sub> could reduce infectious symptoms and antibiotic consumption among patients with antibody deficiency or frequent RTIs.

**Design:** A double-blind randomised controlled trial.

**Setting:** Karolinska University Hospital, Huddinge.

**Participants:** 140 patients with antibody deficiency (selective IgA subclass deficiency, IgG subclass deficiency, common variable immune disorder) and patients with increased susceptibility to RTIs (>4 bacterial RTIs/year) but without immunological diagnosis.

**Intervention:** Vitamin D<sub>3</sub> (4000 IU) or placebo was given daily for 1 year.

**Primary and secondary outcome measures:** The primary endpoint was an infectious score based on five parameters: symptoms from respiratory tract, ears and sinuses, malaise and antibiotic consumption. Secondary endpoints were serum levels of 25-hydroxyvitamin D<sub>3</sub>, microbiological findings and levels of antimicrobial peptides (LL-37, HNP1–3) in nasal fluid.

**Results:** The overall infectious score was significantly reduced for patients allocated to the vitamin D group (202 points) compared with the placebo group (249 points; adjusted relative score 0.771, 95% CI 0.604 to 0.985, p=0.04).

**Limitations:** A single study centre, small sample size and a selected group of patients. The sample size calculation was performed using p=0.02 as the significance level whereas the primary and secondary endpoints were analysed using the conventional p=0.05 as the significance level.

**Conclusions:** Supplementation with vitamin D<sub>3</sub> may reduce disease burden in patients with frequent RTIs.

## ARTICLE SUMMARY

### Article focus

- Recent evidence suggests that vitamin D<sub>3</sub> has potent extraskelatal effects, such as suppression of inflammation and strengthening of mucosal immunity by induction of antimicrobial peptides.
- Data from observational studies suggest that low levels of 25-hydroxyvitamin D<sub>3</sub> are associated with an increased risk of respiratory tract infections.
- Results from a limited number of randomised controlled trials on the protective role of vitamin D<sub>3</sub> against respiratory tract infections are inconclusive and thus additional studies are warranted.

### Key messages

- Therefore we designed and carried out a randomised controlled trial where a large dose (4000 IU) of vitamin D<sub>3</sub> was given to patients with an increased susceptibility to infections for 1 year.
- The main conclusion is that vitamin D<sub>3</sub> supplementation reduces symptoms and antibiotic consumption among patients with an increased frequency of respiratory tract infections. Thus, vitamin D<sub>3</sub> supplementation may be an alternative strategy to reduce antibiotic use among patients with recurrent respiratory tract infections.

### Strengths and limitations of this study

- A high daily dose of vitamin D<sub>3</sub> was used, the study time was a full year covering all seasons and patients with an increased frequency of respiratory tract infections were studied.
- A single study centre, small sample size (n=140) and a selected group of patients.

## INTRODUCTION

Vitamin D was discovered when it was noted that rachitic children were improved by exposure to sunlight.<sup>1</sup> It was later shown by Holick *et al*<sup>2</sup> that vitamin D<sub>3</sub> is synthesised in the skin under the influence of ultraviolet light. Vitamin D<sub>3</sub> is further hydroxylated in the liver

to 25-hydroxyvitamin D<sub>3</sub>, which is considered to reflect the vitamin D status of an individual patient.<sup>3</sup> The final activation to the active form 1,25-dihydroxyvitamin D<sub>3</sub> (1,25(OH)<sub>2</sub>D<sub>3</sub>) requires 1- $\alpha$ -hydroxylase activity. This enzyme (also designated CYP27B1) is expressed in the kidney but also in many other cell-types, including epithelial and immune cells.<sup>4</sup> The active vitamin D<sub>3</sub> (1,25(OH)<sub>2</sub>D<sub>3</sub>) binds to the vitamin D receptor (VDR), which belongs to the nuclear receptor family. Active vitamin D<sub>3</sub> is only present in minute amounts in the circulation and local activation in target cells is crucial for vitamin D-mediated effects on the immune system.<sup>5</sup>

Low levels of 25-hydroxyvitamin D<sub>3</sub> are associated with an increased risk of tuberculosis<sup>6–8</sup> and respiratory tract infections.<sup>9</sup> The mechanism is not fully elucidated but vitamin D<sub>3</sub> has been shown to induce antimicrobial peptides in immune cells.<sup>10</sup> In addition, active vitamin D<sub>3</sub> (1,25(OH)<sub>2</sub>D<sub>3</sub>) has broad anti-inflammatory effects on the adaptive immune system by shifting the T helper cell pool from a Th1/Th17-response to a Th2/Treg-dominated response.<sup>11 12</sup> Vitamin D<sub>3</sub> has also been shown to suppress the Th2-response in allergic bronchopulmonary aspergillosis.<sup>13</sup> Thus, vitamin D<sub>3</sub> modulates both the adaptive and innate immune system.<sup>14</sup> The bulk of data on vitamin D<sub>3</sub> and infections stems from in vitro experiments and retrospective observational studies. Results from randomised controlled trials (RCTs) where the effects of vitamin D<sub>3</sub> on infections have been investigated (reviewed by Yamshchikov *et al*<sup>15</sup>) are not conclusive and larger clinical trials are therefore warranted.

We designed a study to test the hypothesis that 4000 IU of vitamin D<sub>3</sub> given daily to patients with antibody deficiency and frequent respiratory tract infections for 1 year could prevent or ameliorate infections. In addition, we investigated whether genetic polymorphisms in genes involved in the effect and/or metabolism of vitamin D<sub>3</sub> have an influence on the outcome of vitamin D<sub>3</sub> supplementation.

## METHODS

### Study design

A prospective, randomised, double-blind placebo-controlled study of vitamin D<sub>3</sub> supplementation in patients with an increased susceptibility to respiratory tract infections. The study was approved by the local Ethical Committee and the Swedish Medical Product Agency and was performed in accordance with the declaration of Helsinki. Written informed consent was obtained from all study participants. The study was registered at [www.clinicaltrials.gov](http://www.clinicaltrials.gov) prior to inclusion of the first patient (NCT01131858). The EudraCT number is 2009-011758-16. The full protocol is available from the corresponding author upon request.

### Sample size calculation

The sample size was based on the assumption that the intervention would reduce the number of days with

symptoms from 42 (210 points) to 28 days (140 points), that is, a reduction of the infectious burden by 30%. Given this assumption, a sample size of 60 patients per study group was predicted to provide the study 90% power at a significance level of  $p=0.02$  (Student's *t* test). To compensate for predicted exclusion of participants, the groups were increased to include 70 patients per treatment arm. Importantly, the significance level of  $p=0.02$  was chosen in the power calculation to ensure that a sufficient number of patients were recruited in order to avoid a type II error in the primary analysis. However, the conventional and widely accepted significance level of  $p=0.05$  was used for statistical analyses of the primary and secondary endpoints.

### Participants

Patients at the Immunodeficiency Unit, Karolinska University Hospital, Huddinge, Sweden, were included between March and June 2010 by the study nurses (SH, ML and KJ). Inclusion criteria were age 18–75 years and an increased susceptibility to respiratory tract infections; that is, >42 days with symptoms from the respiratory tract during a 12-month period prior to study inclusion. Patients registered at the Immunodeficiency Unit are closely followed up with a diary of symptoms and antibiotic consumption. Thus, the patients are trained and used to apply such an instrument to assess their infectious status. Data from patients' standard diary were used as an instrument in order to assess patients for eligibility, both via telephone and by the responsible physician (PB and ACN) prior to inclusion. Patients with selective IgA-deficiency (*D80.2*), IgG-subclass deficiency (*D80.3*) and common variable immune disorder (CVID, *D83.0*) as well as patients without a defined immunological diagnosis (*D89.9*) were included. Exclusion criteria were prophylactic treatment with antibiotics, history of hypercalcaemia or stones in the urinary tract, sarcoidosis, ongoing supplementation with vitamin D<sub>3</sub> exceeding 400 IU/day, HIV-infection and pregnancy.

### Interventions

Patients were randomised to 12 months' treatment with vitamin D<sub>3</sub> (Vigantol, 4000 IU/day, Merck GmbH, Darmstadt, Germany) or placebo oil. One drop contained 500 IU vitamin D<sub>3</sub> or placebo oil (Miglyol oil, Merck GmbH, Darmstadt, Germany) and the participants were asked to take eight drops daily. The participants had to mark their daily symptoms of infection in a diary, which was sent via regular mail to the study site every month. The following data were recorded: symptoms from the respiratory tract, ears and sinuses, treatment with antibiotics, numbers of bacterial cultures, times and reasons of visits to hospitals, frequency of travelling abroad and adherence to study drug.

### Outcomes

The primary outcome was a composite infectious score, based on a daily patient-reported questionnaire and

included five parameters: symptoms from the respiratory tract, ears and sinuses, malaise and use of antibiotics (see online supplementary figure S1), each parameter gave 1 point/day. The occurrence of x-ray verified pneumonia gave three additional points per day for a period of 7 days. Thus, a pneumonia resulted in  $3 \times 7$  points = 21 extra points. Patients were specifically instructed to record only symptoms related to ongoing respiratory tract infections. Symptoms related to infections at other sites (urinary tract, wounds, etc) as well as non-infectious symptoms were reported as adverse events. Secondary outcomes were serum levels of 25-hydroxyvitamin D<sub>3</sub> (at baseline and after 3, 6, 9 and 12 months), numbers of bacterial cultures, microbiological findings and levels of antimicrobial peptides (LL-37 and HNP1-3) in nasal fluid (at baseline and after 6 and 12 months). In addition, six post hoc genotype analyses were performed in all participants. Analyses of single nucleotide polymorphisms (SNPs) were carried out for VDR (Taq1 and Foq1), CYP27B1, CYP24A1, CYP2R1 and vitamin D binding protein (GC). Safety tests included plasma levels of creatine, calcium, phosphate and albumin, measured at baseline and after 3, 6, 9 and 12 months. At inclusion, urine-HCG (human chorionic gonadotropin) in women was measured and p-parathyroid hormone was measured in both genders. The results of the safety tests were reviewed by an independent and unblinded consultant physician. Two blinded physicians (PB and ACN) were responsible for inclusion and all medical visits to the study site (Immunodeficiency Unit, Karolinska University Hospital, Huddinge, Sweden).

### Randomisation and statistical analysis

Participants were randomised to 12 months' treatment with vitamin D<sub>3</sub> (Vigantol, 4000 IU/day) or placebo oil. Block randomisation with a block size of ten was used to ascertain equal group sizes. Staff at Karolinska Trial Alliance was responsible for randomisation procedures. In the statistical analysis, continuous variables were compared using Mann-Whitney U test or linear regression and dichotomous variables by Fisher's exact test or logistic regression. Regressions of log-transformed infectious scores were performed both unadjusted (simple regression) and with adjustment for potential confounders (multiple regression).

### Statistical methods: primary analysis

The distribution of the infectious score was found to be skewed, thereby violating the normal assumption of the prespecified t test analysis. Hence, scores were log-transformed prior to analysis. Further, the randomisation had resulted in age distributions that were not entirely balanced between the two groups. Since there might be concerns that such imbalance could influence the results of the study, the original analysis plan was extended with a multivariable analysis adjusting for potential confounders. In this linear regression model based on log-transformed values of the primary outcome

(the total infectious score) and its individual components, adjustment was made for age, gender, smoking, type of immune deficiency and significant comorbidities (respiratory or non-respiratory). Because of the transformation procedure, the adjusted effect of vitamin D<sub>3</sub> is expressed as a ratio between the score in the vitamin D<sub>3</sub> and the placebo group. In this multiplicative model, an effect size of 1 indicates identical outcome in the two study groups and statistically non-significant results are recognised by CIs encompassing the value 1.

To explore potential divergent effects on different organ systems, both adjusted and unadjusted analyses were repeated separately for each individual item of the infectious score. In addition, the temporal aspects of the vitamin D<sub>3</sub> effect were investigated by dividing the study period into four 90-day periods (starting on the first day of treatment) and repeating the analyses separately for each time period. 'Ear' and 'sinus' symptoms as well as 'antibiotic use' occurred at low frequencies and for these entities normal distributions could not be achieved despite data transformation. Thus, the adjusted analyses of these individual items were based on multivariable logistic regression, after coding the symptom (or antibiotic therapy) as present or absent during the course of the study. However, this only applies to analysis of the individual items, and not to the primary analysis of the total infectious score, where all item scores were added as originally described.

Most postrandomisation exclusions were due to patients failing to fill out the symptoms diary. Hence, no intention-to-treat (ITT) analysis based on actual outcome data could be performed. However, the potential impact of dropouts was addressed in an ITT analysis based on multiple imputation of missing outcome data. In the imputation process, pooled estimates were derived from 100 datasets created by means of multivariate imputation by chained equations and predictive mean matching for the same covariates as in the adjusted per-protocol analysis.

Detailed descriptions of randomisation and blinding, sampling of nasal fluid, measurement of antimicrobial peptides, measurement of 25-hydroxyvitamin D<sub>3</sub>, genotyping and statistical analyses of secondary outcomes are presented in the supplementary methods section.

## RESULTS

### Baseline data

A total of 286 patients were first assessed for eligibility but 144 were not included because they did not fulfil all inclusion criteria; <42 days with infection/year (n=35), lacked other inclusion criteria (n=42), or declined to participate (n=67). The remaining 142 patients were further screened and 140 patients were included in the study. Of these, 70 were randomised to vitamin D<sub>3</sub> supplementation and 70 to placebo (figure 1). The groups did not differ with regard to gender, IgG replacement therapy, smoking, baseline 25-hydroxyvitamin D<sub>3</sub> levels,




Figure 1 Study outline.

type of immune defect or comorbidities (table 1). Patients with subclass deficiency, selective IgA deficiency (sIgAD), CVID and patients without a defined immunological diagnosis (ND) but with >4 bacterial respiratory tract infections/year were included. IgG replacement therapy was most common in the CVID group (100%) and in the subclass deficiency group (63%), and also frequent in the other groups (ND, 54% and sIgAD, 38%, see online supplementary table S1). Patients allocated to the placebo group were slightly younger than patients in the treatment group (p=0.025, data not shown). During the course of the study, 16 patients left the study prematurely (8 patients from each study group) and consequently 124 patients were included in the main per-protocol analysis. Reasons for dropout included elevated parathyroid hormone (n=2), withdrawn consent (n=5), adverse events (n=1), prescription of vitamin D outside the study (n=1), failure to complete diary (n=4) or non-compliance to study medication (n=3; figure 1).

**Primary endpoint: infectious score**


One year of vitamin D<sub>3</sub> treatment was associated with a significantly reduced total infectious score both in the unadjusted (n=124, p=0.024; table 2) and in the adjusted analyses (n=124, p=0.040; table 2; figure 2A,B and see online supplementary table S2). The

Table 1 Baseline data

	Vitamin D <sub>3</sub>	Placebo
Number	70	70
Age (mean)	55.4	50.8
Female	52/70	50/70
Male	18/70	20/70
IgG-replacement	39/70	42/70
Smoking	4/70	6/70
25-OH levels (mean) (nmol/l)	51.5	46.9
Immunological diagnosis		
sIgA-deficiency	9/70	9/70
IgG subclass	27/70	30/70
CVID	6/70	4/70
ND	28/70	27/70
Concomitant disease		
No other disease	16/70	18/70
Lung: Asthma	27/70	25/70
Lung: BE	5/70	7/70
Lung: COPD	5/70	4/70
Other disease*	17/70	16/70

Mann-Whitney U test was used for comparisons of age and 25-OH vitamin D<sub>3</sub>. Fisher's exact test was used for all other comparisons.

\*'other disease' includes hypertension, body pain, hypothyroidism and gastritis as most common diagnoses. BE, bronchiectasis; COPD, chronic obstructive pulmonary disease; CVID, common variable immunodeficiency; ND, increased susceptibility to infections without a defined immunological disorder.



**Figure 2** Primary endpoint. The adjusted total relative infectious score (A) is expressed ‘per quarter’ (3-month periods). The adjusted 1-year scores (total score, airway, malaise, ear, sinus and antibiotics) are depicted in a Forest-plot (B) together with 95% CI. Effects are presented as relative scores (total score, airway and malaise) or OR (ear, sinus, antibiotics and indicated with asterisks).

unadjusted relative score in the intervention group was 0.754 (95% CI 0.591 to 0.963, p=0.024, n=124) corresponding to a 25% reduction and after adjustment

for potential confounders, the relative score was 0.771 (95% CI 0.604 to 0.985, p=0.04), corresponding to a 23% reduction (table 2). According to the temporal analysis, the effect of vitamin D<sub>3</sub> supplementation tended to improve with time (figure 2A). The absolute unadjusted score per patient was 202 points for the vitamin D group and 249 points for the placebo group, a significant reduction of 47 points per patient (p=0.023, Mann-Whitney U test, see online supplementary table S3).

When the individual items of the infectious score were analysed separately, all point estimates indicated a reduction in the treatment group (table 2, see online supplementary figure S2), although only antibiotic consumption reached statistical significance (figure 2B and see online supplementary figure S2, panel E). The adjusted OR for antibiotic use was 0.365 (95% CI 0.153 to 0.872, p=0.023, n=124), that is, a 63.5% reduction of the odds of antibiotic use in the intervention group (table 2). The absolute values were 33 days on antibiotics for the placebo group and 16 days for the vitamin D<sub>3</sub> group, that is, a reduction of 17 days in the vitamin D<sub>3</sub> group (see online supplementary table S3). The temporal trends for specific symptoms and antibiotic consumption were similar to the total score and reached statistical significance for ‘ear’-symptoms (n=124, p=0.041) and for ‘malaise’ (n=124, p=0.053) in the final quarter of the study (see online supplementary figure S2, panels B and C).

Analysing the primary outcome according to ITT (n=140) produced results virtually identical to those of the per-protocol analysis. In the unadjusted ITT analysis, vitamin D<sub>3</sub> reduced the total infectious score by 25% (relative score 0.752, 95% CI 0.588 to 0.962, p=0.024) and after adjustment for potential confounders the reduction was 23% (relative score 0.767, 95% CI 0.599 to 0.982, p=0.036).


### Serum levels of 25-hydroxyvitamin D<sub>3</sub>

Serum 25-hydroxyvitamin D<sub>3</sub> levels did not differ between the groups at baseline (table 1) but already after 3 months

**Table 2** Primary endpoint

Endpoint	Univariable regression model (unadjusted values)			Multiple regression model (adjusted values)		
	Effect	95% CI	p Value	Effect	95% CI	p Value
Total score	0.754	0.591 to 0.963	0.024	0.771	0.604 to 0.985	0.040
Airway	0.857	0.697 to 1.053	0.141	0.871	0.706 to 1.074	0.200
Ear*	0.721	0.352 to 1.465	0.367	0.695	0.320 to 1.501	0.357
Sinus*	0.583	0.280 to 1.198	0.144	0.594	0.265 to 1.328	0.204
Malaise	0.845	0.692 to 1.032	0.098	0.845	0.689 to 1.036	0.108
Antibiotics*	0.355	0.154 to 0.784	0.012	0.365	0.153 to 0.872	0.023

Treatment effect calculated as the ratio between infectious scores in the vitamin D<sub>3</sub> and the placebo groups. Due to low frequencies, endpoints marked with asterisks (\*) were coded as binary outcomes (ie, present or absent in each patient) and compared by means of logistic regression. In these cases, the effect refers to OR of experiencing the outcome at least once during the course of the study (The data are based on n=124 patients).



**Figure 3** Secondary endpoint. Vitamin D levels. Serum was collected at days 0, 3, 6, 9 and 12 months and levels of 25-hydroxyvitamin D<sub>3</sub> were measured. Values are expressed as mean±95% CI.

the intervention group had a significantly higher level of 25-hydroxyvitamin D<sub>3</sub> (133.4 vs 66.6 nmol/l, p<0.001; figure 3). This increase remained throughout the study (figure 3).

**Bacterial cultures and microbiology**

During the course of the study, 173 microbiological samples were obtained in the vitamin D<sub>3</sub> group (n=62, 2.79/patient) and 301 in the placebo group (n=62, 4.85/patient; p=0.010; table 3). The number of samples with at least one positive finding was higher in the placebo group, with close to statistical significance (p=0.052), while the fraction of positive samples was similar for both groups (table 3). Significantly more patients had a microbiological sample taken from the respiratory tract (≥1 sample) during the study period in the placebo group; OR 2.63 (95% CI 1.17 to 5.92; table 3).

In total, the vitamin D<sub>3</sub> group generated 76 positive microbiological findings (bacteria or fungi), compared with 159 in the placebo group (p=0.023). There was no difference between the groups for the traditional respiratory pathogens (*Haemophilus influenzae*, *Moraxella catharralis* and *Streptococcus pneumoniae*), but there were

significantly fewer findings of *Streptococcus aureus* (p=0.019) and fungi (p=0.028, *Candida* spp. and *Aspergillus* spp.) in the treatment group (table 4). Likewise, significantly fewer vitamin D<sub>3</sub>-treated patients had a bacterial culture positive for *S aureus* (p=0.019) or fungal species (p=0.058), although the latter difference did not reach statistical significance (table 4).

Vitamin D treated patients with subclass deficiency left significantly fewer bacterial or fungal cultures than placebo-treated patients with this diagnosis; seven cultures in the vitamin D group (n=22) versus 47 cultures in the placebo group (n=24) (see online supplementary table S4). Also the number of patients that had ≥1 bacterial culture taken was significantly fewer in the placebo group (12/22 vs 22/24, p=0.0065, see online supplementary table S4). There was no significant effect of other immunological diagnoses on bacterial cultures or microbiology (see online supplementary table S4).

Since concomitant lung disease may be an important factor for vitamin D mediated effects on respiratory immunity, we performed a detailed analysis of bacterial cultures and microbiology of patients with asthma, bronchiectasis (BE) and chronic obstructive pulmonary disease (COPD). The numbers of patients with these diagnoses were quite small, which preclude any firm conclusions regarding any effect. However, there was a trend—however not significant—that vitamin D-treated patients with asthma produced fewer bacterial cultures (average 2.9 cultures/patient vs 7.0 cultures/patients, p=0.080, see online supplementary figure S3) and fewer positive cultures than placebo-treated asthmatics (average 0.6 positive cultures/patients vs 2.7/patient in the placebo group, p=0.052, see online supplementary figure S3). In addition, vitamin D-treated asthma patients showed significantly fewer cultures positive for fungi (*Candida* and *Aspergillus*) compared with placebo-treated asthmatics (p=0.0476, see online supplementary table S5). For BE or COPD patients there was no clear trend or significant effect in bacterial cultures or microbiology.

**Levels of antimicrobial peptides in nasal fluid**

There was no statistically significant difference between the vitamin D<sub>3</sub> or placebo groups when nasal fluids were analysed for the presence of antimicrobial peptides (AMPs). Initially, the levels of both LL-37 and HNP1-3 tended to be higher in the placebo group (see online supplementary figure S3, panels A and B). However, after 12 months the microbiological pattern was reversed and no primary pathogens could be detected in nasal swabs from vitamin D<sub>3</sub>-treated patients (n=25, p=0.039; see online supplementary figure S4, panel C). The placebo-treated patients exhibited the same mix between normal flora and primary pathogens at all three sampling points (0, 6 and 12 months; see online supplementary figure S4, panel C).

**SNP variants and treatment effect**

Most genetic variants did not affect the primary endpoint. However, patients carrying the ‘AA’ genotype in

**Table 3** Bacterial cultures

	Vitamin D <sub>3</sub>	Placebo	Significance
Number of samples per patient (mean, n=62/62)	2.79	4.85	p=0.010*
Number of positive samples per patient (mean, n=62/62)	1.01	2.02	p=0.052*
Fraction positive cultures (%)	63/173 (36%)	125/301 (41%)	p=0.28**
Patients with ≥1 sample taken	38/62 (61%)	50/62 (81%)	p=0.029**

\*Mann-Whitney U test.  
\*\*Fisher's exact test.

**Table 4** Microbiological findings

Microorganism	Number of findings (total)			Number of patients		
	Vitamin D <sub>3</sub>	Placebo	MW-U	Vitamin D <sub>3</sub>	Placebo	Fisher
<i>Haemophilus influenzae</i>	28	27	p=0.46	10/62	13/62	p=0.64
<i>Moraxella catharralis</i>	8	17	p=0.39	7/62	10/62	p=0.60
<i>Streptococcus pneumoniae</i>	7	6	p=0.74	4/62	5/62	p=1.00
<i>Staphylococcus aureus</i>	6	33	p=0.010	4/62	14/62	p=0.019
<i>Enterobacteriaceae</i>	8	8	p=0.39	4/62	7/62	p=0.53
<i>Pseudomonas aeruginosa</i>	8	15	p=0.68	3/62	4/62	p=1.00
Fungal infection	11	53	p=0.028	4/62	12/62	p=0.058
Total	76	159	p=0.023			

Mann-Whitney U test was used to analyse the total number of findings, whereas Fisher's exact test was used for analysis of the number of patients (fraction) with a specific finding.

the CYP2R1-gene, encoding the 25-hydroxylase enzyme, had a larger benefit of vitamin D<sub>3</sub>-supplementation (-55%) compared to AG or GG carriers (-6%) (n=124, p=0.046 for interaction, see online supplementary table S6).

### Adverse events

In total, the vitamin D<sub>3</sub> group reported 38 adverse events (AEs) versus 56 AEs in the placebo group. The most common symptoms in the treatment group were headache (n=5) and lumbago (n=5), whereas placebo-treated patients reported paresthesias (n=8), diverticulitis (n=4) and urinary tract infection (n=4) as most frequent AEs (table 5, see online supplementary table S7). There was a general trend towards the number of adverse events being higher in the placebo group. Significantly more patients in the placebo group reported cardiovascular problems, such as heart failure, hypertonia and thrombosis (p=0.028). For gastrointestinal and other (non-respiratory) infections there was also a trend favouring the vitamin D<sub>3</sub> group (p=0.058 and 0.09, respectively). No clinically relevant changes in serum levels of calcium, phosphate, creatine or

albumin could be observed (see online supplementary figure S5). There was one severe adverse event in each group (rhabdomyosarcoma in the vitamin D<sub>3</sub> group and lung bleeding in the placebo group), both judged as being unrelated to the study drug.

### DISCUSSION

The main conclusion from this long-term RCT is that vitamin D<sub>3</sub> supplementation reduces the total burden of respiratory tract infections. The primary endpoint was composed of five different parameters that patients recorded daily throughout the study year. All point estimates favoured the vitamin D<sub>3</sub> group and a statistically significant effect was seen on both the total score and on the probability of receiving antibiotics (p<0.05). The effect on the infectious score was evident both in analysis per-protocol and according to ITT, and withstood adjustment for potential confounders. In addition, the number of bacterial cultures and microbiological findings was significantly reduced in the intervention group. These findings are potentially important and support that Vitamin D<sub>3</sub> supplementation may prevent respiratory tract infections and reduce antibiotic consumption, particularly in patients with hypogammaglobulinaemia or with an increased frequency of respiratory tract infections.

However, our study has several limitations: First, the choice of primary endpoint may be questioned since it relies solely on patient-reported information. To compensate for inherent problems with patient-reported data, the evaluation instrument was designed to cover many aspects of an infectious episode, including various symptoms as well as antibiotic consumption. Together the reported data formed an 'infectious score', which constituted the primary endpoint of the study. Similar composite scores have successfully been applied to different diseases, such as tuberculosis (TB-score<sup>16</sup>), pneumonia (CURB-65<sup>17</sup>) and bacterial meningitis (BMS-score<sup>18</sup>). Notably, vitamin D supplementation had a major effect on the odds of taking antibiotics during the study period (a reduction by 63.5%). In addition, the absolute number of days on antibiotics was reduced by 50% (from 33 days in the placebo group to 16 days in

**Table 5** Adverse events

Organ	Vitamin D <sub>3</sub> n (%)	Placebo n (%)	p Value
CNS	11 (29)	10 (18)	1.00
Gastrointestinal	4 (11)	12 (21)	0.058
Cardiovascular	0 (0)	6 (11)	0.028
Infections (other than RTI)	2 (5)	8 (14)	0.09
Musculoskeletal	10 (26)	10 (18)	1.00
Respiratory (non-infectious)	2 (5)	4 (7)	0.68
Skin	5 (13)	2 (4)	0.44
Other	4 (10)	4 (7)	1.00
Total	38	56	

Number of reports. Fisher's exact test was used for between group comparison (the data are based on AE-reports from n=62 patients/arm).

CNS, central nervous system, RTI, respiratory tract infection.

the intervention group), which was statistically significant both in the adjusted and unadjusted analyses (table 1). However, despite the relatively modest reduction for the other components of the primary endpoint the overall infectious score was significantly reduced—mainly as a result of the large effect on the antibiotic parameter—both in the unadjusted and in the adjusted analyses (table 1 and figure 2). It is important to interpret the statistical significance in light of our power calculation, which was based on a significance level of  $p=0.02$ . In the power calculation, the significance level was reduced from 0.05 to 0.02 in order to increase the statistical power at the  $p=0.05$  level. This approach was incorrect, and the targeted power (at the  $p=0.05$  level) should instead have been increased without altering the  $p$ -value threshold. However, we have used the widely accepted significance level  $p=0.05$  in the statistical analyses for both the primary and secondary endpoints, respectively. Another potential problem was that the patient population was very heterogeneous with regard to immune deficiency and concomitant diseases. We adjusted for these factors in the multivariable analyses of the primary endpoint, but the sample sizes in each subgroup were too small to draw any conclusions of effects in specific disease groups. However, a detailed post hoc analysis of the relation between immunological diagnosis, concomitant lung disease and the secondary endpoints ‘taken bacterial cultures’, ‘positive bacterial cultures’ and ‘microbiological findings’ was performed. There was a clear trend that vitamin D-treated patients with subclass deficiency and/or asthma produced fewer bacterial cultures, fewer positive cultures and fewer fungal cultures (see online supplementary tables S4 and S5 and figure S3). Although this analysis may lack precision by the small number of patients included, it could have clinical implications regarding target groups for vitamin D<sub>3</sub> supplementation.

Nevertheless, our double-blind RCT has several strengths. For example, we chose a high daily dose of vitamin D<sub>3</sub> based on published calculations on metabolism and effects on immunity.<sup>14 19</sup> Other RCTs using lower doses of vitamin D<sub>3</sub>, 400–2000 IU/day, have mainly been negative with regard to the prevention of infections.<sup>20 21</sup> However, one study using 1200 IU/day showed a significant reduction of influenza among school children in Japan.<sup>22</sup> Notably, also studies using higher doses of vitamin D<sub>3</sub> have been negative. Martineau *et al* used 400 000 IU vitamin D<sub>3</sub> during 42 days (9523 IU/day) with the aim of shortening time to sputum conversion in tuberculosis. No significant effect on the primary endpoint could be observed in that study, except in a subgroup with the *tt* genotype in the VDR gene.<sup>23</sup> A recent study investigated whether 100 000 IU vitamin D<sub>3</sub>/month (3333 IU/day) could reduce the incidence of COPD exacerbations. There was no significant effect on the primary endpoint, although a post hoc analysis revealed that patients with a low vitamin D<sub>3</sub> level at baseline had a significant effect of vitamin D<sub>3</sub> supplementation.<sup>24</sup>

Importantly, our study is the first to utilise high daily doses for an extended period of one full year. Thus, we covered all four seasons, which was important in Sweden with a known seasonal variation in 25-hydroxyvitamin D<sub>3</sub> levels.<sup>25</sup> Two previous RCTs were performed during the winter season—when vitamin D levels are low—but only during 4<sup>22</sup> and 6 months,<sup>20</sup> respectively. Previous RCTs have been conducted during shorter periods; 42 days,<sup>23</sup> 6 weeks<sup>26</sup> and 12 weeks,<sup>21</sup> respectively. Interestingly, we observed a clear time-dependent effect suggesting that a long-term supplementation approach (>6 months) may be necessary to affect immunity. To expand on the results of a previous study in healthy individuals where no difference between the intervention and placebo groups was observed,<sup>21</sup> we chose a study population with frequent RTIs and at least 42 days with infection during the year prior to inclusion. Notably, patients in the study represent a selected group of individuals with frequent RTI, although the immune disorders that they represent (sIgAD, IgG-subclass deficiency and patients with no defined immune disorder) are generally mild in character and dominated by mucosal RTIs. We also included a small number of CVID-patients, which can be considered to be a more severe immune disorder, but all these patients are treated with IgG replacement therapy and thus well controlled. Hence, the results from this study cannot directly be applied to the general healthy population. Nevertheless, the results provide solid support for additional interventional studies of vitamin D<sub>3</sub>, especially in groups consuming large amounts of antibiotics.

The mechanism of the observed effects remains largely unknown. Vitamin D<sub>3</sub> modulates the immune response at many levels, such as induction of AMPs, skewing of T-cells from Th1/Th17 to Tregs as well as general anti-inflammatory effects.<sup>14</sup> Here, we investigated the role of AMPs in nasal fluid. However, we could not detect any significant changes of LL-37 or HNP1-3 during the study period, but noted that placebo-treated patients tended to have higher levels of AMPs after 1 year of treatment. This was paralleled by a shift of the microflora in the nasal compartment that could explain the unexpected finding of higher AMP-levels in the placebo group. Recently, it was shown that 1,25(OH)<sub>2</sub>-vitamin D<sub>3</sub> induces both HNP1-3 and LL-37 in nasal fluid of healthy volunteers,<sup>27</sup> supporting that LL-37 may indeed be induced in vivo. However, our study design did not allow such conclusions but rather support that vitamin D<sub>3</sub> affect mucosal immunity, leading to a shift of the microflora. Recently, we showed that the bacterial composition in nasal swabs is an important determinant of AMP-levels in nasal fluid.<sup>28</sup>

Given that vitamin D<sub>3</sub> induces LL-37 in epithelial cells and that LL-37 kills bacteria in vitro, we expected a reduction of the classical bacterial pathogens *H influenzae*, *M catharralis* and *S pneumoniae* in the intervention group. However, the frequency of these bacteria was not reduced



but a reduction of *S aureus* and fungal species that often colonise the airways was observed. This could be explained by specific effects by vitamin D<sub>3</sub> on immunity against *S aureus*. In fact, vitamin D<sub>3</sub> induces human  $\beta$ -defensin-2 (HBD-2) with bactericidal activity against *S aureus*.<sup>29</sup> A recent study showed that low vitamin D<sub>3</sub> levels were associated with an increased risk of being colonised by this bacterium.<sup>30</sup> Further, vitamin D<sub>3</sub> affects immunity against *C albicans*, which indicates direct effects of vitamin D<sub>3</sub> on human immunity.<sup>31</sup> Alternatively, it is possible that vitamin D<sub>3</sub> may have prevented symptomatic viral infections, which prompted patients to leave a bacterial sample from the airways. Interestingly, there is both mechanistic and clinical evidence that vitamin D<sub>3</sub> can prevent viral infections,<sup>32–34</sup> although we did not address this in the current study.

Notably, we observed a prominent increase in the serum concentration of 25-hydroxyvitamin D<sub>3</sub>, which indicated good compliance and tolerability of the study drug. In fact, there was a trend towards adverse events being reported more often in the placebo group, suggesting that vitamin D<sub>3</sub> possibly could be efficient against other diseases, but this observation requires further studies. No clinically relevant changes of blood chemistry (calcium, phosphate, albumin or creatine) were observed. Despite few adverse events and high tolerability, 16 exclusions occurred during the study year. The main reason was problems to adhere to the protocol and 6/16 patients dropped out of the study after a few weeks. The rest failed to send in the diaries, did not leave blood for monitoring of safety parameters or did not take the study drug. One patient was excluded based on symptoms that could be attributed to vitamin D<sub>3</sub> (facial paraesthesia). However, this patient was later confirmed to have been allocated to placebo.

In summary, we found that supplementation with vitamin D<sub>3</sub> reduced the total infectious score with 47 points per patient (23% reduction in the adjusted analysis) during the study year. The observed reduction was lower than the assumed reduction of 70 points per patient (predefined assumption: 210 points=>140 points; a reduction of 30%) that formed the basis for the power calculation. However, despite the predefined level of a reduction of infectious score by 30% as a clinically meaningful effect, we believe that effects lower than this also could be relevant for the individual patient. We base this line of reasoning on the fact that a reduction of 47 points per patient can be translated into 47 days with cough (47 points), 23 days with ear and sinus symptoms (23×2=46 points) or 9 days with cough, sinus and ear symptoms together with malaise and antibiotics (9×5=45 points). In addition, our data indicate that vitamin D<sub>3</sub> supplementation reduces the odds of taking antibiotics by approximately 60% in patients with frequent respiratory tract infections. Thus, supplementation with vitamin D<sub>3</sub> could provide a novel strategy to reduce antibiotic use among high consumers and indirectly prevent the emerging epidemic of bacterial resistance.

#### Author affiliations

<sup>1</sup>Department of Laboratory Medicine, Clinical Microbiology, Karolinska Institutet, Stockholm, Sweden

<sup>2</sup>Clinical Immunology, Immunodeficiency Unit, Karolinska University Hospital, Stockholm, Sweden

<sup>3</sup>Department of Medicine, Center for Infectious Medicine (CIM), Karolinska Institutet, Stockholm, Sweden

<sup>4</sup>Department of Laboratory Medicine, Clinical Immunology, Karolinska Institutet, Stockholm, Sweden

<sup>5</sup>Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden

<sup>6</sup>Department of Laboratory Medicine, Clinical Pharmacology, Karolinska Institutet, Stockholm, Sweden

**Contributors** PB designed the study, collected, analysed and interpreted data, wrote the paper. A-CN designed the study, collected and interpreted data, wrote the paper. SH designed and coordinated the study, collected and interpreted data. RSR carried out experimental work and analysed data. BA analysed and interpreted data, wrote the paper. LB-B analysed and interpreted data, wrote the paper. LE analysed and interpreted data. JL analysed and interpreted data, wrote the paper. JA designed the study, interpreted data, wrote the paper.

**Funding** The study was supported by grants from Swedish Research Council Projects 2009-2950 (JA) and 2010-4199 (BA). Strategic Research Foundation (SSF), Swedish Heart and Lung foundation, Karolinska Institutet, Stockholm County Council, Swedish Cancer Society, Magnus Bergwall and Åke Wiberg foundations. Merck GmbH provided the study drug (Vigantol) but did not have any influence on study design, analysis of data, writing or decision to publish.

**Competing interests** None.

**Patient consent** Obtained.

**Ethics approval** The study was approved by the local Ethical Committee and the Swedish Medical Product Agency and was performed in accordance with the declaration of Helsinki. Written informed consent was obtained from all study participants.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** There are no additional data available.

#### REFERENCES

- Hess AF, Unger LJ, Pappenheimer AM. Experimental rickets in rats. III. The prevention of rickets in rats by exposure to sunlight. *J Biol Chem* 1922;50:77–81.
- Holick MF, MacLaughlin JA, Clark MB, *et al*. Photosynthesis of previtamin D<sub>3</sub> in human skin and the physiologic consequences. *Science* 1980;210:203–5.
- Holick MF. Vitamin D deficiency. *N E J M* 2007;357:266–81.
- Hansdottir S, Monick MM. Vitamin D effects on lung immunity and respiratory diseases. *Vitam Horm* 2011;86:217–37.
- Hewison M. Antibacterial effects of vitamin D. *Nat Rev Endocrinol* 2011;7:337–45.
- Gibney KB, MacGregor L, Leder K, *et al*. Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-Saharan Africa. *Clin Infect Dis* 2008;46:443–6.
- Martineau AR, Nhamoyebonde S, Oni T, *et al*. Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. *Proc Natl Acad Sci USA* 2011;108:19013–17.
- Wilkinson RJ, Llewelyn M, Toossi Z, *et al*. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. *Lancet* 2000;355:618–21.
- Ginde AA, Mansbach JM, Camargo CA Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. *Arch Inter Med* 2009;169:384–90.
- Liu PT, Stenger S, Li H, *et al*. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. *Science* 2006;311:1770–3.
- Daniel C, Sartory NA, Zahn N, *et al*. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. *J Pharmacol Exp Ther* 2008;324:23–33.

12. Lemire JM, Archer DC, Beck L, *et al.* Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. *J Nutr* 1995;125(6 Suppl):1704S–8S.
13. Kreindler JL, Steele C, Nguyen N, *et al.* Vitamin D3 attenuates Th2 responses to *Aspergillus fumigatus* mounted by CD4+ T cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis. *J Clin Invest* 2010;120:3242–54.
14. Hewison M. Vitamin D and immune function: an overview. *Proc Nutr Soc* 2012;71:50–61.
15. Yamshchikov AV, Desai NS, Blumberg HM, *et al.* Vitamin D for treatment and prevention of infectious diseases: a systematic review of randomized controlled trials. *Endocr Pract* 2009;15:438–49.
16. Wejse C, Gustafson P, Nielsen J, *et al.* TBscore: signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course. *Scand J Infect Dis* 2008;40:111–20.
17. Bauer TT, Ewig S, Marre R, *et al.* CRB-65 predicts death from community-acquired pneumonia. *J Intern Med* 2006;260:93–101.
18. Dubos F, De la Rocque F, Levy C, *et al.* Sensitivity of the bacterial meningitis score in 889 children with bacterial meningitis. *J Pediatr* 2008;152:378–82.
19. Heaney RP, Davies KM, Chen TC, *et al.* Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. *Am J Clin Nutr* 2003;77:204–10.
20. Laaksi I, Ruohola JP, Mattila V, *et al.* Vitamin D supplementation for the prevention of acute respiratory tract infection: a randomized, double-blinded trial among young Finnish men. *J Infect Dis* 2010;202:809–14.
21. Li-Ng M, Aloia JF, Pollack S, *et al.* A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections. *Epidemiol Infect* 2009;137:1396–404.
22. Urashima M, Segawa T, Okazaki M, *et al.* Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. *Am J Clin Nutr* 2010;91:1255–60.
23. Martineau AR, Timms PM, Bothamley GH, *et al.* High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. *Lancet* 2011;377:242–50.
24. Lehouck A, Mathieu C, Carremans C, *et al.* High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. *Ann Intern Med* 2012;156:105–14.
25. Lindh JD, Andersson ML, Eliasson E, *et al.* Seasonal variation in blood drug concentrations and a potential relationship to vitamin D. *Drug Metab Dispos* 2011;39:933–7.
26. Nursyam EW, Amin Z, Rumende CM. The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. *Acta medica Indonesiana* 2006;38:3–5.
27. Thijs W, Janssen K, Verhoosel RM, *et al.* Effect of vitamin D treatment on antimicrobial peptides in asthma patients and healthy controls, Conference Abstract, European Respiratory Society, 2011.
28. Cederlund A, Olliver M, Rekha RS, *et al.* Impaired release of antimicrobial peptides into nasal fluid of hyper-IgE and CVID patients. *PLoS One* 2011;6:e29316.
29. Wang TT, Nestel FP, Bourdeau V, *et al.* Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. *J Immunol* 2004;173:2909–12.
30. Olsen K, Falch BM, Danielsen K, *et al.* Staphylococcus aureus nasal carriage is associated with serum 25-hydroxyvitamin D levels, gender and smoking status. The Tromso Staph and Skin Study. *Eur J Clin Microbiol Infect Dis* 2012;31:465–73.
31. Khoo AL, Chai LY, Koenen HJ, *et al.* 1,25-Dihydroxyvitamin D3 modulates cytokine production induced by *Candida albicans*: impact of seasonal variation of immune responses. *J Infect Dis* 2011;203:122–30.
32. Beard JA, Bearden A, Striker R. Vitamin D and the anti-viral state. *J Clin Virol* 2011;50:194–200.
33. Hansdottir S, Monick MM, Lovan N, *et al.* Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-linked chemokines and cytokines in airway epithelium while maintaining the antiviral state. *J Immunol* 2010;184:965–74.
34. Sabetta JR, DePetrillo P, Cipriani RJ, *et al.* Serum 25-hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults. *PLoS One* 2010;5:e11088.